Ajooni biotech

AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)
Corp Office: H.No 1769, Phase 3B2, Mohali-160059
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

August 14, 2026

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

Subject: Outcome of the Board Meeting held on Friday, August 14, 2026, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

SYMBOL: AJOONI

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Friday, August 14 2026 at 03.00 p.m concluded at 03.45 p.m. Following transactions were considered and approved:

1. Un-audited Financial Results for the quarter ended June 30, 2026.
2. Limited Review Report from the auditor for the quarter ended June 30, 2026.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

JASJOT SINGH
Digitally signed by JASJOT SINGH
Date: 2026.08.14 15:53:21 +05'30'

Jasjot Singh
Managing Director
DIN: 01937631

AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026(In Lakhs)

	PARTICULARS	QUARTER ENDED					Year Ended (Audited)
		30.06.2026	31.03.2026	30.06.2025	Period Ended (UnAudited)	Period Ended (UnAudited)	31.03.2026
					30.06.2026	30.06.2025	
I	**Income**						
	Revenue from operations	6,349.07	6,062.21	3,126.77	6,349.07	3,126.77	18,237.81
	Other income	26.89	130.43	64.54	26.89	64.54	241.81
	Total income from operations	**6,375.96**	**6,192.64**	**3,191.31**	**6,375.96**	**3,191.31**	**18,479.62**
II	**Expenses**						
	Cost of Material Consumed	5,454.86	4,915.56	2,564.17	5,454.86	2,564.17	14,805.33
	Change In Inventories	(39.06)	(0.83)	(4.18)	(39.06)	(4.18)	(12.54)
	Employee benefit expenses	137.59	127.78	99.21	137.59	99.21	457.29
	Finance costs	48.21	28.95	8.46	48.21	8.46	72.94
	Depreciation and amortization expenses	80.27	89.79	24.83	80.27	24.83	220.63
	Payment to NSE						
	Other expenses	628.65	919.36	396.10	628.65	396.10	2,362.14
	Total expenses	**6,310.52**	**6,080.61**	**3,088.59**	**6,310.52**	**3,088.59**	**17,905.79**
III	**Profit/(Loss) before exceptional items and tax**	**65.44**	**112.03**	**102.72**	**65.44**	**102.72**	**573.83**
IV	**Exceptional items**						
V	**Profit/(Loss) before tax**	**65.44**	**112.03**	**102.72**	**65.44**	**102.72**	**573.83**
VI	**Tax expenses**						
	a) Current tax	18.62	28.17	22.50	18.62	22.50	153.01
	b) Deferred tax	3.64	10.86	2.08	3.64	2.08	11.37
	b) Mat Credit						
VII	**Net Profit/(Loss) for the period/year**	**43.18**	**94.72**	**78.14**	**43.18**	**78.14**	**432.19**
VIII	**Other comprehensive income (net of tax)**				-		
	loss:		84.03		-		**(120.94)**
	Total other comprehensive income		**84.03**				**(120.94)**
IX	**Total comprehensive income for the period/year (VII+VIII)**	**43.18**	**10.69**	-	**43.18**	-	**311.10**
X	**Paid-up equity share capital (face value of the share shall be indicated)**	**3,444.87**	**3,444.87**	**3,444.87**	**3,444.87**	**3,444.87**	**3,444.87**

XI	Other equity (excluding revaluation reserve)	5,717.45	5,674.27	5,441.16	5,717.45	5,441.16	5,674.27
XII	EPS in Rs. (Face Value of Rs.10/- each)*				-		
	-Basic	0.01	0.05	0.02	0.01	0.02	0.25
	-Diluted	0.01	0.05	0.02	0.01	0.02	0.25

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 12.08.2026 after being reviewed by the Audit Committee.

2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN: 01937631

JASJOT SINGH
Digitally signed by JASJOT SINGH
Date: 2026.08.14 15:53:36 +05'30'

Place : Mohali
Date : 14/08/2026

AJOONI BIOTECH LIMITED
CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities
For the Year ended on 30th June 2026

in Rs. (Lakhs)

PARTICULARS	30TH JUNE 2026	31ST MARCH 2026
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	2,948.92	2,585.57
b) Capital Work In Progress	0.00	0.00
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets	35.94	35.95
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	233.18	244.75
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets	1,500.00	1,500.00
i) Deffered Tax Asset (net)	52.94	49.29
j) Other Non Current Asset	273.07	173.30
(2) Current Assets		
a) Inventories	4,181.02	3,945.51
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	1,656.08	1,783.43
(3) Cash & Cash Equivalent	37.36	41.90
(4) Bank Balances other than (iii) above		
(5) Loans	1,366.60	1,414.92
(6) Other Financial Asset		69.98
c) Current Tax Assets (net)		-
d) Other Current Asset	205.77	191.91
TOTAL	12,490.88	12,036.51
II EQUITY AND LIABILITIES		
(1) Equity		
a) Equity Share Capital	3,444.87	3,444.87

AJOONI BIOTECH LTD. MOHALI

b) Other Equity	5,717.45	5,674.28
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	140.83	154.00
(2) Trade Payables		
(3) Other Financial Liabilties		
b) Employee Benefit Obligations	30.34	28.65
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	2,550.27	1,622.28
(2) Trade Payables	560.02	891.41
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	1.90	1.69
c) Other Current Liabilities	26.58	66.32
d) Current tax liabilities (Net)	18.62	153.01
TOTAL	**12,490.88**	**12,036.51**

Place : Mohali
Date : 14.08.2026

For Ajooni Biotech Limited

AJOONI BIOTECH LTD. MOHALI

Jasjot Singh
Managing Director
DIN: 01937631

JASJOT SINGH
Digitally signed by JASJOT SINGH
Date: 2026.08.14 15:53:47 +05'30'

NARINDER KUMAR AND COMPANY
CHARTERED ACCOUNTANTS

SCO 65-B (1st Floor) City Heart,
Kharar Chandigarh Road,
Kharar, SAS Nagar Mohali-140301
Mobile : 98154 50065
Email : nkgargca@yahoo.co.in

Limited Review Report

Ref. No. .... Dated ....

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th June 2026.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY
Chartered Accountants

NARINDER KUMAR & COMPANY
S.C.O. 65-B
(1st Floor), City Heart
Kharar-Chandigarh Road
Kharar, Mohali -140301
FRN-0030737N
Chartered Accountants

(NARINDER KUMAR GARG)
PARTNER
M.NO-080287

Date:-14.08.2026
UDIN:- 26080287YCZIRL9409